tradingkey.logo

Twist Bioscience Corp

TWST
View Detailed Chart
31.320USD
+0.360+1.16%
Close 11/11, 16:00ETQuotes delayed by 15 min
1.88BMarket Cap
LossP/E TTM

Twist Bioscience Corp

31.320
+0.360+1.16%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.16%

5 Days

+4.19%

1 Month

+0.42%

6 Months

+1.62%

Year to Date

-32.60%

1 Year

-33.76%

View Detailed Chart

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Twist Bioscience Corp's Score

Industry at a Glance

Industry Ranking
38 / 159
Overall Ranking
99 / 4611
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Buy
Current Rating
42.317
Target Price
+39.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Twist Bioscience Corp Highlights

StrengthsRisks
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 53.75% year-on-year.
Undervalued
The company’s latest PE is -21.59, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 71.88M shares, increasing 1.04% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 6.40M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.78.

Twist Bioscience Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Twist Bioscience Corp Info

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
Ticker SymbolTWST
CompanyTwist Bioscience Corp
CEODr. Emily M. Leproust, Ph.D.
Websitehttps://www.twistbioscience.com/
KeyAI